Clinical Diagnostics Market Outlook Report 2025-2030 | Software-Driven Innovation and Liquid Biopsy Tech Intensify Competition with Traditional Tissue Biopsy Providers and Molecular Diagnostics Firms

Dublin, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The "Clinical Diagnostics Outlook, 2025" report has been added to ResearchAndMarkets.com's offering.

This research service provides a global outlook for the clinical diagnostics market, along with a 5-year revenue forecast from 2025 to 2030.

To succeed in 2025 and beyond, companies must act with agility, invest in high-value areas, and prioritize innovation. Those that adopt AI, expand decentralized testing, and enter emerging markets will be best positioned for sustained growth.

The market analysis covers three core segments. Centralized Testing includes clinical chemistry and immunoassays (CC&IA), hematology, hemostasis, and molecular diagnostics, with detailed coverage of CC&IA and molecular diagnostics. Referral and Peripheral Testing comprises tissue diagnostics and clinical microbiology, with in-depth insights into tissue diagnostics. Decentralized Testing encompasses point-of-care testing (POCT) and self-monitoring blood glucose (SMBG), with a strong focus on the POCT segment.

The global clinical diagnostics market is poised for strong growth as stakeholders shift focus toward high-growth segments such as precision medicine, decentralized diagnostics, software-driven solutions, and product expansion. Companies continue to adopt LIMS and other digital platforms while emerging opportunities in the POCT sector further drive market momentum. The growing elderly population continues to drive demand for chronic disease testing. At the same time, advances in technology are opening new possibilities in genetic and biomarker testing, allowing stakeholders to prioritize personalized medicine - particularly in developing countries that are investing heavily in clinical diagnostics and healthcare infrastructure.

Innovators are increasingly defining the landscape through software-based solutions and broader product portfolios. Developers of liquid biopsy technologies have transformed oncology diagnostics by enabling the non-invasive detection of circulating tumor cells and cell-free DNA. This shift has intensified competition between traditional tissue biopsy providers and molecular diagnostics firms.

The growing adoption of liquid biopsy tests, such as Delfi Diagnostics' FirstLook Lung (LDT) and Guardant Health's Shield blood test for early colorectal cancer detection, reflects this transition toward personalized, non-invasive diagnostics. Pharmaceutical companies are driving this trend by investing in biomarker-based tests, which position oncology and rare disease diagnostics as key growth areas. Continued progress in precision medicine and molecular diagnostics enhances the accuracy and scalability of predictive testing.

Asia-Pacific (APAC) continues to drive the market's fastest growth. Analysts project double-digit sales increases in 2025, as countries like India and China adopt digital pathology and affordable molecular diagnostics at scale. Companies such as MGI Tech are meeting this demand by launching automated next-generation sequencing (NGS) solutions to expand diagnostic access. In collaboration with Universidad de San Martin de Porres, MGI also strengthens genetic research by applying NGS to identify genetic risk factors that support future public health initiatives. Across these markets, government-led healthcare reforms are enabling long-term industry expansion.

Meanwhile, large companies continue to find substantial opportunities in the United States. Industry leaders are accelerating consolidation by acquiring niche technology providers to enhance their portfolios. For example, Danaher strengthened its protein research and diagnostics capabilities by acquiring Abcam. This integration contributed to a 10% revenue increase over 2024 by incorporating innovative products into existing offerings.

Key Topics Covered:

Analysis Highlights

The 2024 Clinical Diagnostics Industry: Forecast vs. ActualHistorical AnalyticsTop Clinical Diagnostics Predictions for 2025

Strategic Imperatives

Why is it Increasingly Difficult to Grow?The Strategic ImperativeThe Impact of the Top 3 Strategic Imperatives on the Clinical Diagnostics IndustryGrowth Opportunities Fuel the Growth Pipeline Engine

Growth Environment

SegmentationGrowth Environment

Macroeconomic Factors

Global Economy Beat Expectations in 2024, Growing at 3.2%Trump 2.0 to Drive Growth Slowdown and Inflationary PressuresGlobal Growth Slowdown to 2.8%, Avoiding a Recession in 2025; Weaker China to Weigh on Asia Pacific GrowthGlobal Growth Slows to 2.8% in 2025, Recession Averted; Weaker China Expected to Weigh on APAC OutlookGlobal Macroeconomic Shifts and Resilience Strategies: Tech Integration, R&D, and Agile Production Ecosystems Will Ensure Short-term Resiliency

Impact of US Tariffs

US Tariffs - 2025 AnalysisUS Tariffs - Implications for Key Stakeholders in the Clinical Diagnostics IndustryGlobal Supply Chains Are Being Reshaped by Trade Tariffs, Which Will Drive Decentralization and Open New Growth Opportunities in the Clinical Diagnostics Industry

Revenue Trends, 2025

Forecast ConsiderationsClinical Diagnostics Industry by SegmentRevenue Forecast by SubsegmentRevenue Forecast by Segment - Centralized TestingRevenue Forecast by Segment - Referral and Peripheral and Decentralized TestingEnd User Analysis for Centralized, Referral and Peripheral, and Decentralized TestingRevenue Forecast by RegionRevenue Forecast Analysis by RegionRegional Regulatory Framework and Reimbursement Policy

Competitive Environment

Revenue ShareRevenue Share AnalysisCompetitor MatrixNotable Activities

Top 5 Predictions - 2025

Prediction 1 - CDx to Drive the Next Era of Precision Medicine, Becoming the Cornerstone of Innovation by 2025Prediction 2 - LIMS Integration to Revolutionize Life Sciences, Driving Data-driven Innovation Beyond $2 BillionPrediction 3 - Multi-omics Diagnostics to Propel a Paradigm Shift in Disease CharacterizationPrediction 4 - DaaS to Disrupt Traditional Labs and Usher in a New Era of On-demand TestingPrediction 5 - Decentralized Molecular Testing to Redefine Healthcare Access in Emerging Markets, with Global Market Expected to Surpass $24 Billion by 2025

Clinical Diagnostics Outlook

2024 Industry Snapshot

CC&IA - 2025

CC&IA Industry SnapshotCC&IA Industry - Companies to Watch

Molecular Diagnostics - 2025

Molecular Diagnostics Industry SnapshotMolecular Diagnostics Industry - Companies to Watch

POCT - 2025

POCT Industry SnapshotPOCT Industry - Companies to Watch

Tissue Diagnostics - 2025

Tissue Diagnostics Industry SnapshotTissue Diagnostics Industry - Companies to Watch

Growth Opportunity Universe

Growth Opportunity 1: LIMS for Improved Predictive AnalysisGrowth Opportunity 2: Companion Diagnostics CDx Expanding Beyond OncologyGrowth Opportunity 3: Multiplex POCT for Rapid AMR Antimicrobial Resistance Diagnostics

Conclusions

Conclusions and Future Outlook

Next Steps

Benefits and Impacts of Growth Opportunities

For more information about this report visit https://www.researchandmarkets.com/r/jey1wt

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.